Long-term Follow up after Transfemoral Transcatheter Aortic Valve Implantation in Lower Risk Patients Using the Balloon-Expandable Bioprosthesis: Gender-Dependent Outcomes

Authors

  • Dritan Useini, MD Department of Cardiothoracic Surgery, University Hospital Bergmannsheil, Ruhr University Bochum, Germany
  • Markus Schlömicher, MD Department of Cardiothoracic Surgery, University Hospital Bergmannsheil, Ruhr University Bochum, Germany
  • Assem Aweimer, MD Department of Cardiology and Angiology, University Hospital Bergmannsheil, Ruhr University Bochum, Germany
  • Peter Haldenwang, MD, PhD Department of Cardiothoracic Surgery, University Hospital Bergmannsheil, Ruhr University Bochum, Germany
  • Justus Strauch, MD, PhD Department of Cardiothoracic Surgery, University Hospital Bergmannsheil, Ruhr University Bochum, Germany
  • Polykarpos C Patsalis, MD Department of Medicine, Division of Cardiology and Emergency Medicine, Knappschaft University Hospital, Ruhr University Bochum, Germany

DOI:

https://doi.org/10.1532/hsf.4451

Keywords:

transfemoral transcatheter aortic valve implantation

Abstract

Introduction: Long-term data on gender-related outcomes after transfemoral transcatheter aortic valve implantation (TF-TAVI) using newer generations heart valves in lower-risk patients are sparse. We aimed to evaluate gender-dependent long-term outcomes after TF-TAVI in lower-risk patients using the third-generation balloon expandable bioprosthesis.

Methods: Data of 103 patients undergoing TF-TAVI using the third-generation balloon expandable bioprosthesis were analyzed. We conducted up to six years follow up and performed comparison on gender basis: men (45 patients; 82 ± 4.7 years; STS Score 3.7 ± 1.6%) vs. women (58 patients; 83.2 ± 4.5 years; STS Score 3.6 ± 1.8%). The mean follow-up time was 30 months.

Results: Cardiovascular risk factors at baseline were similar, without significant differences between men and women. The 30-day mortality was 4.4% in men vs. 3.4% in women (P = 0.745). The 30-day stroke was 4.4% in men vs. 1.7% in women (P = 0.582). The major vascular injury rate and the pacemaker rate was 2.3% vs. 10.7% (P = 0.134) and 19.5% vs. 18.9% (P = 1) in men vs. women, respectively. There was a significant difference of mean long-term survival: men, 42.1 months [95%CI: 33.154–51.101] vs. women, 57.3 months [95%CI: 50.618–64.159], P = 0.015.

Conclusion: Although considerably more prone to procedural complications, women had a significantly long-term survival benefit after TF-TAVI in lower-risk patients despite similar baseline characteristics.

References

Influence of gender on clinical outcomes following transcatheter aortic valve implantation from the UK transcatheter aortic valve implantation registry and the National Institute for Cardiovascular Outcomes Research. Am J Cardiol. Feb 1;113:522-8.

Azarbaijani Y, O'Callaghan K, Sanders WE, Wu C, Laschinger J, Marinac-Dabic D, et al. 2018. Sex-Specific Outcomes After Transcatheter Aortic Valve Replacement: A Review of the Literature. Cardiol Rev. Mar/Apr;26:73-81.

Bière L, Launay M, Pinaud F, Hamel JF, Eltchaninoff H, Iung B, et al. 2015. Influence of sex on mortality and perioperative outcomes in patients undergoing TAVR: insights from the FRANCE 2 registry. J Am Coll Cardiol. Feb 24;65:755-7.

Buchanan GL, Chieffo A, Montorfano M, Maisano F, Latib A, Godino C, et al. 2011. The role of sex on VARC outcomes following transcatheter aortic valve implantation with both Edwards SAPIEN™ and Medtronic CoreValve ReValving System® devices: The Milan registry. EuroIntervention. 7:556–63.

Buja P, Napodano M, Tamburino C, Petronio AS, Ettori F, Santoro G, et al. 2013. Comparison of variables in men versus women undergoing transcatheter aortic valve implantation for severe aortic stenosis (from Italian Multicenter CoreValve registry) Am J Cardiol. Jan 1;111:88-93.

Chandrasekhar J, Dangas G, Yu J, Vemulapalli S, Suchindran S, Vora AN, et al. 2016. Sex-Based Differences in Outcomes With Transcatheter Aortic Valve Therapy: TVT Registry From 2011 to 2014. J Am Coll Cardiol. Dec 27;68:2733-44.

Forrest JK, Adams DH, Popma JJ, Reardon MJ, Deeb GM, Yakubov SJ, et al. 2016. Transcatheter Aortic Valve Replacement in Women Versus Men (from the US CoreValve Trials). Am J Cardiol. Aug 1;118:396-402.

Hayashida K, Morice MC, Chevalier B, Hovasse T, Romano M, Garot P, et al. 2012. Sex related differences in clinical presentation and outcome of transcatheter aortic valve implantation for severe aortic stenosis. J Am Coll Cardiol. 59:566–71.

Husser O, Pellegrini C, Kessler T, Burgdorf C, Thaller H, Mayr NP, et al. 2016. Predictors of Permanent Pacemaker Implantations and New-Onset Conduction Abnormalities With the SAPIEN 3 Balloon-Expandable Transcatheter Heart Valve. JACC Cardiovasc Interv. Feb 8;9:244-54.

Kappetein AP, Head SJ, Généreux P, Piazza N, van Mieghem NM, Blackstone EH, et al. 2012. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. Eur Heart J. Oct;33:2403-18.

Mack MJ, Leon MB, Thourani VH, Makkar R, Kodali SK, Mark R, et al. 2019. PARTNER 3 Investigators. Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients. N Engl J Med. May 2;380:1695-705.

Murray MI, Geis N, Pleger ST, Kallenbach K, Katus HA, Bekeredjian R, et al. 2015. First experience with the new generation Edwards Sapien 3 aortic bioprosthesis: procedural results and short term outcome. Interv Cardiol. Feb;28:109-16.

Nazif TM, Chen S, George I, Dizon JM, Hahn RT, Crowley A, et al. 2019. New-onset left bundle branch block after transcatheter aortic valve replacement is associated with adverse long-term clinical outcomes in intermediate-risk patients: an analysis from the PARTNER II trial Eur Heart J. Jul 14;40:2218-27.

O’Connor SA, Morice MC, Gilard M, Gilard M, Leon MB, Webb JG, et al. 2015. Revisiting sex equality with transcatheter aortic valve replacement outcomes: A collaborative, patient-level meta-analysis of 11,310 patients. J Am Coll Cardiol. 66:221–8.

Stangl V, Baldenhofer G, Laule M, Baumann G, Stangl K. 2014. Influence of sex on outcome following transcatheter aortic valve implantation (TAVI): systematic review and meta-analysis. J Interv Cardiol. Dec;27:531-9.

Tarantini G, Baumgartner H, Frank D, Husser O, Bleiziffer S, Rudolph T, et al. 2021. Four-year mortality in women and men after transfemoral transcatheter aortic valve implantation using the SAPIEN 3. Catheter Cardiovasc Interv. Apr 1;97:876-84.

Wang TY, Gracia E, Callahan S, Bilfinger T, Tannous H, Pyo R, et al. 2019. Gender Disparities in Management and Outcomes Following Transcatheter Aortic Valve Implantation With Newer Generation Transcatheter Valves. Am J Cardiol. May 1;123:1489-93.

Webb J, Gerosa G, Lefèvre T, Leipsic J, Spence M, Thomas M, et al. 2014. Multicenter evaluation of a next-generation balloon-expandable transcatheter aortic valve. J Am Coll Cardiol. Dec 2;64:2235-43.

Williams M, Kodali SK, Hahn RT, Humphries KH, Nkomo VT, Cohen DJ, et al. 2014. Sex-related differences in outcomes after transcatheter or surgical aortic valve replacement in patients with severe aortic stenosis: Insights from the PARTNER Trial (Placement of Aortic Transcatheter Valve). J Am Coll Cardiol. 63:1522–8.

Zhao ZG, Liao YB, Peng Y, Chai H, Liu W, Li Q, et al. 2013. Sex-related differences in outcomes after transcatheter aortic valve implantation: a systematic review and meta-analysis. Circ Cardiovasc Interv. 6:543–51.

Published

2022-03-08

How to Cite

Useini, D., Schlömicher, M., Aweimer, A., Haldenwang, P., Strauch, J., & Patsalis, P. (2022). Long-term Follow up after Transfemoral Transcatheter Aortic Valve Implantation in Lower Risk Patients Using the Balloon-Expandable Bioprosthesis: Gender-Dependent Outcomes. The Heart Surgery Forum, 25(2), E175-E180. https://doi.org/10.1532/hsf.4451

Issue

Section

Article